CRB experts coauthor BioPhorum white paper on multi-modal manufacturing 

As biopharmaceutical pipelines expand to include mAbs, viral vectors, mRNA, cell therapies, and emerging modalities, manufacturers are seeking more flexible ways to design and operate facilities. A newly released white paper from BioPhorum Technology Strategy explores how multi-modal manufacturing can help organizations adapt faster, reduce capital risk, and future-proof their operations. 

We are proud to share that CRB experts Allan Bream, Senior Fellow, Biopharmaceutical Process, and Peter Walters, Fellow, Advanced Therapies, are coauthors of the white paper, Pathway to Multi-Modal Manufacturing. Developed through cross-industry collaboration, the paper brings together practical insight and industry expertise. 

The paper provides a clear view of what multi-modal manufacturing looks like in practice, outlining key drivers, the business case for flexibility, facility design considerations, and strategies to manage risks such as cross-contamination and changeover complexity. Rather than prescribing a single solution, it offers balanced guidance to help leaders make informed, long-term decisions. 

Download the Pathway to Multi-Modal Manufacturing white paper to learn how multi-modal approaches can support flexibility, speed to market, and long-term value.